Thomas Edward Hamilton net worth and biography

Thomas Hamilton Biography and Net Worth

Director of Larimar Therapeutics

Tom Hamilton is currently the Co-founder of the CureFA Foundation, a non-profit research group investing in all areas to advance a cure for Friedreich’s Ataxia. Mr Hamilton is also a Director and Executive Committee member of the Friedreich’s Ataxia Research Alliance (FARA). Mr Hamilton also serves on the board of Annaly Capital Management and CFI Inc. Prior to his work in biotech, he was a managing director and strategic advisor to the head of fixed income, currencies and commodities at Barclays Capital in New York. Mr. Hamilton was responsible for the build out of the Global Securitized Products businesses at Barclays along with Municipal Trading and Investment Banking. Prior to Barclays Tom worked at Citigroup Global Markets and began his career at Salomon Brothers, Inc. in New York.

What is Thomas Edward Hamilton's net worth?: The estimated net worth of Thomas Edward Hamilton is at least $2.66 million as of July 6th, 2026. Mr. Hamilton owns 714,798 shares of Larimar Therapeutics stock worth more than $2,659,049 as of July 14th. This net worth approximation does not reflect any other investments that Mr. Hamilton may own. Learn More about Thomas Edward Hamilton's net worth.
How do I contact Thomas Edward Hamilton?: The corporate mailing address for Mr. Hamilton and other Larimar Therapeutics executives is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. Larimar Therapeutics can also be reached via phone at (844) 511-9056 and via email at [email protected]. Learn More on Thomas Edward Hamilton's contact information.
Has Thomas Edward Hamilton been buying or selling shares of Larimar Therapeutics?: Over the course of the past ninety days, Thomas Edward Hamilton has bought $167,000.00 of Larimar Therapeutics stock. Most recently, on Monday, July 6th, Thomas Edward Hamilton bought 50,000 shares of Larimar Therapeutics stock. The stock was acquired at an average cost of $3.34 per share, with a total value of $167,000.00. Following the completion of the transaction, the director now directly owns 714,798 shares of the company's stock, valued at $2,387,425.32. Learn More on Thomas Edward Hamilton's trading history.
Who are Larimar Therapeutics' active insiders?: Larimar Therapeutics' insider roster includes James Flynn (Director), Thomas Hamilton (Director), and Frank Thomas (Director). Learn More on Larimar Therapeutics' active insiders.
Are insiders buying or selling shares of Larimar Therapeutics?: In the last twelve months, Larimar Therapeutics insiders bought shares 3 times. They purchased a total of 14,425,000 shares worth more than $55,167,000.00. The most recent insider tranaction occured on July, 6th when Director Thomas Edward Hamilton bought 50,000 shares worth more than $167,000.00. Insiders at Larimar Therapeutics own 4.5% of the company. Learn More about insider trades at Larimar Therapeutics.
Information on this page was last updated on 7/6/2026.

Thomas Edward Hamilton Insider Trading History at Larimar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/6/2026	Buy	50,000	$3.34	$167,000.00	714,798
9/16/2022	Buy	317,460	$3.15	$999,999.00	507,590
9/16/2022	Buy	317,460	$3.15	$999,999.00	507,590

Thomas Edward Hamilton Buying and Selling Activity at Larimar Therapeutics

Larimar Therapeutics Company Overview

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Today's Range

Now: $3.74

$3.58

$3.77

50 Day Range

MA: $3.57

$3.05

$4.28

2 Week Range

Now: $3.74

$2.71

$6.42

Volume

343,399 shs

Average Volume

3,070,245 shs

Market Capitalization

$387.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83